Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)
Clinical trial NCT02437136 · COMPLETED
Trial details
- NCT number
- NCT02437136
- Sponsor
- Syndax Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-08-26
- Primary completion
- 2022-09-29
- Enrollment
- 191
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.